Coronavirus Results from phase two of clinical trials
La vacuna de AstraZeneca y la Universidad de Oxford es segura para las personas mayores
Early results from clinical trials for the coronavirus vaccine being developed by AstraZeneca and the University of Oxford show that the vaccine is safe to use for older people.
Results from phase two of clinical trials for this vaccine show that it provides a strong immune response to COVID-19 in adults in their 60s and 70s.
This according to findings from the Lancet, with investigators using data from an experiment with the vaccine on 560 people – 240 of which were over 70 years old.
The results from phase two were said to be promising and showed a prompted a similar immune response to COVID-19 across all age groups.
Very few younger volunteers experienced side effects such as injection pain, fatigue, headaches, fever or muscle pain, while these symptoms were less common in older age groups.
Phase three of the clinical trials of the Oxford vaccine continue to take place and results for those will be known in the coming weeks.